- Barrow Neurological Institute
- Baylor Scott & White Hospital
- Imagion Biosystems
Everyone knows someone affected by cancer
- Less than 5% survive 5 years after diagnosis
- Over half are dead within 18 months
These statistics need to improve.
We have taken an innovative approach to developing new treatments. By in-licensing technologies, and then combining them in a unique way, we believe that we can develop an effective treatment for glioblastoma faster, and at a lower cost, than if we started from “scratch” independently. Collaboration is a critical aspect of our approach.
we are focused on three key technologies:
- Cancer inhibitors: a novel P13K (kinase) inhibitor has shown promise in the lab
- Scintillating nanoparticles: a drug delivery vehicle that can navigate through the bloodstream and small enough to cross the blood-brain barrier to target hard-to-reach tumors like those in the brain
- Cancer biomarkers: how much (or little) of these DNA fragments can identify patients more likely to benefit from treatment and to potentially measure how effective treatment is
The global market for glioblastoma treatments is growing rapidly, with a CAGR of 17.5%. By 2024, analysts estimate that the market will be 3.3 Billion (Source: Drug Development & Delivery).
Once we have established safety and efficacy standards per the requirements of the FDA, we plan to seek partners to advance our treatment through progressive clinical trials and then to commercialize it.
Research takes time and money. Bringing a drug to market now costs an average of $1.3 Billion and at least a decade, according to an analysis published by JAMA (The Journal of American Medical Association).
The unique combination of a drug delivery vehicle (scintiallating nanoparticle) coated in a cancer inhibitor (GCT.Glio.1, our novel P13K inhibitor) are being tested individually in parallel and will ultimately be tested in combination as a potential glioblastoma treatment.
The GCT Leadership team has extensive experience in medical sales, healthcare, and research. GCT also has a deep Scientific Advisory Board comprised of some of the world’s most renowned and highly regarded neurologists, neurosurgeons, and other clinicians.
Use of Proceeds
If the offering's maximum amount of $1,070,000 is raised:
|Use||Value||% of Proceeds|
|Research and Development||$763,177||71.3%|
|Patent and license cost||$50,878||4.8%|
|General and administrative||$101,757||9.5%|
|Legal and Accounting||$50,878||4.8%|
|University Scientific Consulting||$50,880||4.8%|
This is an offering of Class B Common Stock, under registration exemption 4(a)(6), in Global Cancer Technology, Inc. This offering must raise at least $10,000 by April 29, 2022 at 10:59pm ET. If this offering doesn’t reach its target, then your money will be refunded. Global Cancer Technology may issue additional securities to raise up to $1,070,000, the offering’s maximum.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
These financial statements have been audited by an independent Certified Public Accountant.
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
- Apr 30, 2022Primary offering finalized, sellingsharesSold $2 for a total of $2,140shares at
- Apr 6, 2022
- Feb 7, 2022Primary offering of $2shares at
- Feb 7, 2022
- Jan 27, 2022
- Feb 28, 2020
- Feb 18, 2020
- Feb 18, 2020
- Jan 14, 2020
- Nov 19, 2019
- Oct 22, 2019
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email email@example.com instead of commenting.